Hostname: page-component-77c89778f8-5wvtr Total loading time: 0 Render date: 2024-07-18T07:32:11.797Z Has data issue: false hasContentIssue false

Alterations in brain myelination at early-stage schizophrenia detected by macromolecular proton fraction MRI

Published online by Cambridge University Press:  19 July 2023

E. Krupina*
Affiliation:
National Research Nuclear University MEPhI
A. Manzhurtsev
Affiliation:
Clinical and Research Institute of Emergency Pediatric Surgery and Trauma Emanuel Institute of Biochemical Physics of the Russian Academy of Sciences Moscow State University
M. Ublinskiy
Affiliation:
Clinical and Research Institute of Emergency Pediatric Surgery and Trauma
O. Bozhko
Affiliation:
Clinical and Research Institute of Emergency Pediatric Surgery and Trauma
G. Mamedova
Affiliation:
Psychiatric Clinical Hospital 1 named N.A. Alekseev.
V. Ushakov
Affiliation:
National Research Nuclear University MEPhI Psychiatric Clinical Hospital 1 named N.A. Alekseev. Institute for Advanced Brain Studies, Moscow State University, Moscow, Russian Federation
N. Zakharova
Affiliation:
Psychiatric Clinical Hospital 1 named N.A. Alekseev.
V. Yarnykh
Affiliation:
Radiology at the University of Washington, Seattle, United States
D. Andreyuk
Affiliation:
Psychiatric Clinical Hospital 1 named N.A. Alekseev.
M. Shlyapnikov
Affiliation:
Psychiatric Clinical Hospital 1 named N.A. Alekseev.
G. Kostyuk
Affiliation:
Psychiatric Clinical Hospital 1 named N.A. Alekseev.
T. Akhadov
Affiliation:
Clinical and Research Institute of Emergency Pediatric Surgery and Trauma
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

There is evidence that cerebral myelination is impaired in schizophrenia. The purpose of this study is to find the myelin content changes in the brain structures of patients with early-stage schizophrenia using the macromolecular proton fraction (MPF) method, and also to evaluate the differences in the myelination of these structures.

Objectives

To measure MPF in the brain structures of schizophrenia patients

Methods

Forty-five subjects, 22 controls (10m+12f, 31.6±9.7 y.o.) and 23 schizophrenia patients (F20.0, 11m+12f, 31.5±5.1 y.o.). Philips Achieva dStream 3T MRI scanner, standard head coil. The magnetization transfer (TR=20 ms, TE=4.60 ms, FA=10°), T1-weighted (TR=20 ms, TE=4.60 ms, FA=20°) and PD-weighted (TR=20 ms, TE=4.60 ms, FA=4°) were acquired. The MPF maps were reconstructed using home-made software. In FSL, non-brain structures were removed and MPF maps were registered to a standard MNI152 1 mm atlas. Harvard Oxford Cortical and Subcortical atlases were used to select areas of interest. T-test was used in search for between-group differences.

Results

A 3% decrease in myelination in schizophrenia was observed in whole cerebral cortex p = 0.03) and cerebral white matter (p=0.02). Trends to cortical demyelination were found: paracingular cortex (p=0.06), anterior (p=0.1) and posterior cingulate cortex (p=0.07). No myelination disorders were detected in the cerebellum.

Image:

Image 2:

Image 3:

Conclusions

To our knowledge, the absence of cerebellar myelination disorders in patients at an early-stage schizophrenia is reported for the first time, while the observed decrease in cerebrum myelination in schizophrenia is consistent with the previous findings. The difference in myelination between cerebellum and cerebrum may help to characterize the dynamics of the pathological process and provide additional information for understanding the biological mechanisms of the development of schizophrenia.

Grant RSF 20-15-00299 (partially).

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.